Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Gastrointestinal 1Endocrine 1

Conditions

Neoplasms 3Carcinoma, Non-Small-Cell Lung 2Stomach Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Klatskin Tumor 1Gallbladder Neoplasms 1Esophageal Neoplasms 1Cholangiocarcinoma 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Adrenocortical Carcinoma 1

Interventions

Mitotane 10Cisplatin 9pembrolizumab 7Doxorubicin 6Etoposide 5Specimen Handling 4Nivolumab 4Magnetic Resonance Spectroscopy 4relacorilant 3cabozantinib 3Cytoreduction Surgical Procedures 3sodium thiosulfate 2cixutumumab 2cemiplimab 2camrelizumab 2apatinib 2Trastuzumab 2Suramin 2Radiotherapy 2Ipilimumab 2Dichlorodiphenyldichloroethane 2Cyclophosphamide 2tipifarnib 1pegfilgrastim 1milademetan 1lenvatinib 1iodophenyl metomidate 1gossypol acetic acid 1fludarabine phosphate 1entinostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adrenocortical Carcinoma × N-Ac-CHAVC-NH2 × Clear all
NCT00264433 2007-08-06

A Study of the Safety and Effects of ADH-1 Given Intravenously as a Single Agent

Adherex Technologies, Inc.

Phase 2 Completed
EndocrineGastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Esophageal Neoplasms, Carcinoma, Hepatocellular, Neoplasms, Stomach Neoplasms, Adrenocortical Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡